- Published on
KembaraXtra-Medicine – Amaurosis Fugax
Amaurosis fugax is defined as a transient loss of monocular vision caused by temporary retinal ischemia resulting from a reversible occlusion of the ophthalmic artery or its branches. The ophthalmic artery arises from the internal carotid artery, and the central retinal artery is a branch of the ophthalmic artery. This condition is classified under ICD-10CM code G45.3 and is considered an important warning sign of underlying vascular disease.
From an epidemiologic perspective, amaurosis fugax is an uncommon but clinically significant presentation of carotid artery disease in the United States. The peak incidence occurs around 55 years of age, and its recognition is critical because it often represents a form of transient ischemic attack (TIA) with potential risk for future stroke.
The clinical presentation is typically sudden in onset and lasts seconds to minutes. Patients often describe the vision loss as a shade or curtain descending over the eye, most commonly from above downward. The visual deficit may be complete or partial and can involve hemianopic or quadrantic vision loss. During the acute stage, cholesterol emboli, known as Hollenhorst plaques, may sometimes be visualized within the retinal arteries on funduscopic examination.
The etiology of amaurosis fugax is most often embolic in nature. Emboli may originate from the internal carotid artery, usually in the setting of carotid atherosclerotic stenosis, or from the heart, with atrial fibrillation being the most common cardiac source. Carotid artery emboli are typically identified as stenosis on carotid imaging such as CT angiography, MR angiography, or carotid ultrasound. Other important causes include giant cell arteritis, which produces inflammatory occlusion of retinal arteries; hyperviscosity syndromes such as sickle cell disease; hypercoagulable states; and reversible cerebral vasoconstriction syndrome.
In terms of differential diagnosis, retinal migraine must be considered, as it differs by having a gradual onset of visual symptoms over 15 to 20 minutes rather than sudden loss. Transient visual obscurations associated with papilledema also differ, as they are typically brief (1–2 seconds), may be binocular, and are related to transient increases in intracranial pressure. If vision loss persists at the time of evaluation, the differential should be expanded to include arteritic or nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and branch retinal artery occlusion.
The diagnostic workup should prioritize identifying embolic sources, while giant cell arteritis must always be considered, particularly in older adults. A careful retinal examination may reveal an embolus, which can confirm the diagnosis. Auscultation for carotid bruits, examination of peripheral pulses, and assessment for temporal artery tenderness are essential. Patients should be questioned about symptoms suggestive of giant cell arteritis, including headache, scalp tenderness, fever, and jaw claudication. A focused neurologic examination is necessary to evaluate for signs of hemispheric stroke, such as contralateral weakness, sensory loss, or aphasia.
Laboratory evaluation includes a complete blood count along with erythrocyte sedimentation rate and C-reactive protein to assess for inflammation, particularly when giant cell arteritis is suspected. Additional studies include serum chemistries, lipid profile, hemoglobin A1C, cardiac enzymes, and electrocardiography. A hypercoagulable workup may be pursued selectively in younger patients or when the history suggests an underlying thrombophilic disorder.
Imaging studies are central to evaluation. CT or MR angiography of the head and neck is preferred to assess carotid and intracranial vasculature, with carotid ultrasound as an alternative when angiography is contraindicated. MRI of the brain with diffusion-weighted imaging is recommended to identify silent or symptomatic infarcts. Transthoracic echocardiography is used to screen for cardiac embolic sources, while transesophageal echocardiography provides greater sensitivity for detecting left atrial appendage thrombi, patent foramen ovale, ventricular mural thrombus, or aortic arch atheroma. Extended cardiac rhythm monitoring is advised when neither carotid disease nor giant cell arteritis explains the presentation.
Management begins with nonpharmacologic therapy, including dietary modification to reduce saturated fats and cholesterol, regular exercise, and cessation of tobacco and illicit drug use. These measures address the underlying vascular risk factors that contribute to embolic disease.
From an acute management standpoint, amaurosis fugax should be treated as a medical emergency, similar to other forms of TIA. Aspirin therapy should be initiated promptly. If giant cell arteritis is suspected, high-dose prednisone must be started immediately, and the patient should be referred urgently for temporal artery biopsy within 48 hours.
Chronic management focuses on secondary stroke prevention. Carotid endarterectomy is recommended for patients with carotid stenosis greater than 50%, and carotid stenting may be considered in patients who are poor surgical candidates. Aggressive management of vascular risk factors—including hypertension, hyperlipidemia with statin therapy, diabetes, and smoking cessation—is essential. Antiplatelet therapy is indicated for atherosclerotic disease or following carotid intervention, while anticoagulation is required when atrial fibrillation is identified as the etiology.
Regarding prognosis, patients with greater than 50% carotid stenosis who do not undergo carotid endarterectomy and present with transient monocular blindness have an estimated 10% risk of stroke within 3 years, compared with approximately 20% risk in those presenting with hemispheric TIA.
Appropriate referral is critical. As with any TIA, patients should undergo emergent inpatient evaluation at a certified stroke center whenever possible. Carotid endarterectomy or stenting should be considered in patients with ipsilateral high-grade stenosis (≥70%), and may also be appropriate for stenosis of 50%–69% or in patients experiencing multiple TIAs despite optimal medical therapy.
Key clinical pearls include recognizing that visualization of cholesterol emboli in retinal arteries on fundoscopy confirms the diagnosis, understanding that transient visual loss has multiple potential causes, and ensuring that amaurosis fugax is managed with the same urgency as other transient ischemic attacks.
0 Comments
